Venus Remedies Limited
Venus Remedies Limited engages in the pharmaceutical business in India and internationally. It is involved in the research and development of solutions focusing on antimicrobial resistance and oncology. The company also offers analgesic, analgesic and antipyretic, antibiotic, anticoagulant, antiemetic, antiviral, cardiovascular, disinfectant and antiseptic, gastro therapy, hepatoprotective, hormo… Read more
Venus Remedies Limited (VENUSREM) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.136x
Based on the latest financial reports, Venus Remedies Limited (VENUSREM) has a cash flow conversion efficiency ratio of 0.136x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₹811.10 Million) by net assets (₹5.94 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Venus Remedies Limited - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Venus Remedies Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Venus Remedies Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Venus Remedies Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
RoboRobo Co. Ltd
KQ:215100
|
0.000x |
|
Choil Aluminum
KO:018470
|
0.015x |
|
CAB Payments Holdings Limited
PINK:CABPF
|
0.242x |
|
TigerElec Co. Ltd
KQ:219130
|
0.051x |
|
UBM Development AG
VI:UBS
|
-0.015x |
|
Interpark Co. Ltd
KQ:035080
|
0.004x |
|
TOYA S.A. ZY -10
F:6PJ
|
N/A |
|
Fountaine Pajo
PA:ALFPC
|
-0.038x |
Annual Cash Flow Conversion Efficiency for Venus Remedies Limited (2006–2025)
The table below shows the annual cash flow conversion efficiency of Venus Remedies Limited from 2006 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | ₹5.61 Billion | ₹909.20 Million | 0.162x | +111.94% |
| 2024-03-31 | ₹4.88 Billion | ₹372.85 Million | 0.076x | -3.87% |
| 2023-03-31 | ₹4.60 Billion | ₹366.20 Million | 0.080x | -14.55% |
| 2022-03-31 | ₹4.40 Billion | ₹410.01 Million | 0.093x | -71.90% |
| 2021-03-31 | ₹4.00 Billion | ₹1.33 Billion | 0.331x | +39.12% |
| 2020-03-31 | ₹3.23 Billion | ₹770.10 Million | 0.238x | +74.71% |
| 2019-03-31 | ₹3.33 Billion | ₹453.27 Million | 0.136x | -4.09% |
| 2018-03-31 | ₹3.62 Billion | ₹514.36 Million | 0.142x | -35.64% |
| 2017-03-31 | ₹4.52 Billion | ₹997.24 Million | 0.221x | +106.13% |
| 2016-03-31 | ₹4.38 Billion | ₹468.81 Million | 0.107x | -27.85% |
| 2015-03-31 | ₹4.57 Billion | ₹678.05 Million | 0.148x | +30.18% |
| 2014-03-31 | ₹4.62 Billion | ₹526.46 Million | 0.114x | -17.09% |
| 2013-03-31 | ₹3.79 Billion | ₹521.50 Million | 0.138x | +1.44% |
| 2012-03-31 | ₹3.07 Billion | ₹416.70 Million | 0.136x | -13.98% |
| 2011-03-31 | ₹2.37 Billion | ₹373.47 Million | 0.158x | -14.83% |
| 2010-03-31 | ₹1.71 Billion | ₹316.83 Million | 0.185x | +35.37% |
| 2009-03-31 | ₹1.39 Billion | ₹189.50 Million | 0.137x | -36.02% |
| 2008-03-31 | ₹889.86 Million | ₹190.17 Million | 0.214x | -50.89% |
| 2007-03-31 | ₹551.31 Million | ₹239.88 Million | 0.435x | +58.20% |
| 2006-03-31 | ₹318.96 Million | ₹87.73 Million | 0.275x | -- |